FDA Panel Unanimously Supports Luxturna Gene Therapy
- Jane Schuller
- Oct 13, 2017
- 1 min read
Updated: Oct 14, 2020
An FDA advisory panel unanimously backed Spark Therapeutics Luxturna gene therapy for inherited retinal diseases. The one time treatment will be the first gene therapy approved for inherited disease in the USA. Read the full story from Market Scope.
コメント